Drugs / S095012
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05638334 | Nov 2022 → Jun 2024 | neoplasm | Servier | Terminated | No outcome recorded Stop: Business |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | S095012 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05638334 ↗ |
| Modality | Monoclonal antibody | “PD-L1x4-1BB bispecific antibody (S095012)” NCT05638334 ↗ |
| Route | Intravenous | “89Zr-S095012 tracer and S095012 will be administered via an IV infusion” NCT05638334 ↗ |